Arcion Therapeutics (Baltimore, MD) a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain treatment in diabetic neuropathy and post-herpetic neuralgia closed a $8.8M Series A financing. Participants include CMEA Ventures and InterWest Partners.